JP2023531008A5 - - Google Patents
Info
- Publication number
- JP2023531008A5 JP2023531008A5 JP2022578713A JP2022578713A JP2023531008A5 JP 2023531008 A5 JP2023531008 A5 JP 2023531008A5 JP 2022578713 A JP2022578713 A JP 2022578713A JP 2022578713 A JP2022578713 A JP 2022578713A JP 2023531008 A5 JP2023531008 A5 JP 2023531008A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- disorder
- abnormality
- pharmaceutically acceptable
- pharmaceutical product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20181221.1 | 2020-06-19 | ||
| EP20181221 | 2020-06-19 | ||
| EP21164097 | 2021-03-22 | ||
| EP21164097.4 | 2021-03-22 | ||
| PCT/EP2021/066695 WO2021255279A1 (en) | 2020-06-19 | 2021-06-18 | D i h yd rooxazo le and thiourea derivatives modulating the nlrp3 inflammasome pathway |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023531008A JP2023531008A (ja) | 2023-07-20 |
| JP2023531008A5 true JP2023531008A5 (https=) | 2024-06-25 |
Family
ID=76532220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022578713A Pending JP2023531008A (ja) | 2020-06-19 | 2021-06-18 | Ｎｌｒｐ３インフラマソーム経路を調節するジヒドロオキサゾール及びチオ尿素または尿素誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230250070A1 (https=) |
| EP (1) | EP4168395B1 (https=) |
| JP (1) | JP2023531008A (https=) |
| KR (1) | KR20230028425A (https=) |
| CN (1) | CN115768754B (https=) |
| AU (1) | AU2021291065B2 (https=) |
| BR (1) | BR112022025612A2 (https=) |
| CA (1) | CA3178361A1 (https=) |
| IL (1) | IL299084A (https=) |
| MX (1) | MX2022014709A (https=) |
| WO (1) | WO2021255279A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3823974A1 (en) | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| CN118541366A (zh) * | 2021-12-22 | 2024-08-23 | Ac免疫有限公司 | 二氢噁唑衍生物化合物 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU723895B2 (en) | 1997-01-29 | 2000-09-07 | Pfizer Inc. | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| KR102727059B1 (ko) * | 2015-02-16 | 2024-11-05 | 더 유니버서티 어브 퀸슬랜드 | 설포닐우레아와 관련 화합물 및 그 용도 |
| CN109071454B (zh) | 2016-02-16 | 2023-02-17 | 昆士兰大学 | 磺酰脲和相关化合物及其用途 |
| ES2940611T3 (es) | 2016-04-18 | 2023-05-09 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| US11597706B2 (en) | 2016-04-18 | 2023-03-07 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| EP3272739A1 (en) | 2016-07-20 | 2018-01-24 | NodThera Limited | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| CA3047336A1 (en) | 2017-01-23 | 2018-07-26 | Jecure Therapeutics, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| GB2561540A (en) * | 2017-03-13 | 2018-10-24 | Nodthera Ltd | Chemical compounds |
| AU2017416068A1 (en) | 2017-05-24 | 2019-10-31 | The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Novel compounds and uses |
| EP3634951B8 (en) | 2017-06-09 | 2024-08-21 | Zydus Lifesciences Limited | Novel substituted sulfoximine compounds |
| US11465992B2 (en) | 2017-07-07 | 2022-10-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| US11370776B2 (en) | 2017-07-07 | 2022-06-28 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| CN111094242B (zh) | 2017-07-24 | 2024-02-09 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| RS65492B1 (sr) | 2017-07-24 | 2024-05-31 | Novartis Ag | Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp |
| WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| MX2020001776A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| EP3668862A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| US11542255B2 (en) | 2017-08-15 | 2023-01-03 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| EP3668861A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| JP2020531448A (ja) | 2017-08-15 | 2020-11-05 | インフレイゾーム リミテッド | 新規なスルホンアミドカルボキサミド化合物 |
| US11518739B2 (en) | 2017-08-15 | 2022-12-06 | Inflazome Limited | Sulfonamide carboxamide compounds |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| US11623922B2 (en) | 2017-10-03 | 2023-04-11 | Inflazome Limited | Compounds |
| EP3697758B1 (en) | 2017-10-17 | 2022-07-06 | Novartis AG | Sulphonamides and compositions thereof for treating conditions associated with nlrp activity |
| US12221434B2 (en) | 2017-11-09 | 2025-02-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| KR20200087759A (ko) | 2017-11-09 | 2020-07-21 | 인플라좀 리미티드 | 신규한 설폰아마이드 카복스아마이드 화합물 |
| WO2019092172A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| CR20200588A (es) * | 2018-05-04 | 2021-06-24 | Inflazome Ltd | Compuestos novedosos |
| SG11202012159TA (en) | 2018-07-20 | 2021-01-28 | Hoffmann La Roche | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
| EP3823974A1 (en) | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| KR20210038877A (ko) | 2018-07-25 | 2021-04-08 | 노파르티스 아게 | Nlrp3 인플라마좀 억제제 |
| WO2020157069A1 (en) * | 2019-01-28 | 2020-08-06 | NodThera Limited | Amino heterocyclic compounds and uses thereof |
| JP2022547882A (ja) | 2019-09-06 | 2022-11-16 | インフレイゾーム リミテッド | Ｎｌｒｐ３阻害剤 |
-
2021
- 2021-06-18 MX MX2022014709A patent/MX2022014709A/es unknown
- 2021-06-18 WO PCT/EP2021/066695 patent/WO2021255279A1/en not_active Ceased
- 2021-06-18 EP EP21733822.7A patent/EP4168395B1/en active Active
- 2021-06-18 IL IL299084A patent/IL299084A/en unknown
- 2021-06-18 US US18/010,032 patent/US20230250070A1/en active Pending
- 2021-06-18 CA CA3178361A patent/CA3178361A1/en active Pending
- 2021-06-18 AU AU2021291065A patent/AU2021291065B2/en active Active
- 2021-06-18 KR KR1020237002124A patent/KR20230028425A/ko active Pending
- 2021-06-18 BR BR112022025612A patent/BR112022025612A2/pt unknown
- 2021-06-18 JP JP2022578713A patent/JP2023531008A/ja active Pending
- 2021-06-18 CN CN202180043283.6A patent/CN115768754B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023531008A5 (https=) | ||
| EP2928885B1 (en) | Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases | |
| JP2022017447A5 (https=) | ||
| JP2021530536A5 (https=) | ||
| HRP20211225T1 (hr) | Sulfoniluree i srodni spojevi i njihova uporaba | |
| JP2021532101A5 (https=) | ||
| TWI758300B (zh) | 免疫調節劑化合物 | |
| JP2022530985A5 (https=) | ||
| JP2023508142A5 (https=) | ||
| JP7843705B2 (ja) | Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物 | |
| CA2777290C (en) | Process for the preparation of f-series prostaglandins | |
| EP4482823A1 (en) | Di-cyclopropyl based il-17a modulators and uses thereof | |
| US20230348437A1 (en) | Compounds, compositions and methods | |
| EP3986879A1 (en) | Fused 1,2 thiazoles and 1,2 thiazines which act as nl3p3 modulators | |
| JP2022536160A5 (https=) | ||
| WO2019167982A1 (ja) | 飽和環縮合ジヒドロピリミジノン又はジヒドロトリアジノン化合物及びその医薬用途 | |
| CN115768754B (zh) | 调节nlrp3炎症小体通路的二氢噁唑和硫脲或脲衍生物 | |
| HRP20240896T1 (hr) | Derivati sulfoniluree i njihova upotreba | |
| JP2017525684A5 (https=) | ||
| CN110612286A (zh) | 氰基取代的稠合双环衍生物及其制备方法和用途 | |
| CN116836176B (zh) | 青蒿素类化合物、其制备方法和应用 | |
| EP4452972A1 (en) | Dihydro-oxazol derivative compounds | |
| JP2026065124A (ja) | アミノ酸誘導体の結晶形及びその製造方法 | |
| JP2026009006A (ja) | ピリダジノン化合物及びその医薬用途 | |
| RU2021103834A (ru) | Соединения сульфонилмочевины в качестве ингибиторов активности интерлейкина-1 |